65,437 trials
Pneumococcal Infections
Primary: Percentage of Participants With a Solicited Injection-site Adverse Event — 43.9; 36.0; 25.3; 25.6 Percentage of participants — p== 0.003
Dementia · Mild Cognitive Impairment · Alzheimer Disease
Primary: 3 Months Assessment for Center for Epidemiological Studies Depression Scale (CES-D) — 16.05; 18.39 units on a scale
Metastatic Castration-resistant Prostate Cancer · Metastatic Breast Cancer
Primary: Number of Participants With Serious Adverse Events (SAEs) — 16 Participants
HIV Infections · Pregnancy Related
Primary: Maternal HIV Incidence — 0.38; 0.31 incidence/100 Person years
Conscious Sedation · Simple Lacerations Less Than 4 cm · Lumbar Punctures
Primary: ED Length of Stay After Intranasal Midazolam or Nitrous Oxide Administration — 24.5; 18.5; 9; 10 minutes
Advanced Malignant Solid Neoplasm
Primary: Number of Participants With an Objective Response — 0; 0; 0; 0 Participants
PreDiabetes · Glucose Metabolism Disorders · Diabetes Mellitus
Primary: Number of Participants With Insulin Resistance — 69 Participants
Diabetes · Diabetic Foot Ulcer · Peripheral Neuropathy
Primary: Change in Skin Perfusion in Response to Electrical Stimulation Therapy — 65.1; 72.2 mmHg
Central Centrifugal Cicatricial Alopecia
Primary: Mean Change in Physician Global Assessment of Improvement (PGA-I) — 0.07 score on a scale
Alcohol Use
Primary: Change in Alcohol Craving — 0.90; 1.21 score on a scale
Postmenopausal Vulvovaginal Atrophy
Primary: Change From Baseline in Participant's Self-Assessment of Severity of Vaginal Dryness to Week 12/Final Visit — 2.49; 2.46; 2.50; 2.50 score on a scale
Chronic Graft-Versus-Host Disease · Immune System Diseases
Primary: Number of Participants With Complete or Partial Remission of Chronic Graft Versus Host Disease After a First Line Treatment With Arsenic Trioxide — 15 Participants
HIV
Primary: Interleukin 6 (IL-6) Biological Markers — 2.24; 2.63; 2.53; 2.88 pg/mL
Primary Dental Caries, Multisurface Origin (Diagnosis)
Primary: Fitting — 37; 42; 48; 3 Teeth
Prostate Cancer
Primary: Radiographic Progression-free Survival (rPFS) — 8.7; 3.4 Months — p=< 0.001